Saluda Medical Pty, Ltd. appears in FDA device records as the applicant for the Saluda Medical Evoke SCS System, filed under premarket approval number P190002 and product code LGW, the code FDA lists for a totally implanted spinal-cord stimulator for pain relief. The original application was received January 22, 2019, and FDA granted approval on February 28, 2022. The approval letter is addressed to Saluda Medical Pty Ltd at 407 Pacific Highway, Level 1, Artarmon, New South Wales, Australia, and names Monica Early as Head of Regulatory Affairs. That correspondence address is a filing detail, not evidence of a corporate headquarters. [3][10][5]
The approved device and its stated indication
FDA's approval statement describes the Evoke SCS System as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain. The same record classifies the device as a Class 3 totally implanted spinal-cord stimulator for pain relief under product code LGW, reviewed by the Neurology advisory committee. The Summary of Safety and Effectiveness Data repeats the generic and trade names and identifies the applicant as Saluda Medical Pty Ltd at the Artarmon address. [3][5]
Saluda's own clinical manual, filed with FDA, describes use of the Evoke Clinical Interface and Clinical Programming Application with the Evoke Clinical System Transceiver for programming the Evoke SCS System, and its table of contents references the concept of ECAP-controlled closed-loop SCS. The manual lists contact addresses in Artarmon, New South Wales, Australia, and Bloomington, Minnesota, USA. These are labeling and contact details published by the applicant, not independently verified corporate structure. [9]
Original approval and review record
The P190002 approval letter is dated February 28, 2022, and records a filing date of January 22, 2019, with amendments through June 17, 2021. FDA's device record shows the same decision date and a Federal Register notice date of March 4, 2022, with no expedited review flag. The Summary of Safety and Effectiveness Data states that no panel recommendation was made and that FDA's notice of approval was February 28, 2022. [10][3][5]
FDA's PMA database page for P190002 carries a standing note that the device has supplements and that the device description, function or indication may have changed, directing readers to the supplements for current information. The agency's recently approved device page for the Evoke SCS System lists content current as of March 31, 2022, and links to the PMA database entry. [4][8]
Recent supplement activity
Two 30-Day Notice supplements were decided in October 2026. Supplement S051, received September 15, 2026 and decided October 15, 2026, covers a change to the formulation of the adhesive used on the Tyvek packaging of the paddle lead kit. Supplement S052, received September 16, 2026 and decided October 16, 2026, covers approval of additional sterilization chambers at one of Saluda's contract manufacturers. Both carry the decision code OK30, the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and no expedited review flag. [2][1]
How to read the filing record
The supplied collection contains three linked PMA records as of November 20, 2026: two OK30 decisions and one APPR decision. The smaller record sample of three entries shows the same split of two OK30 and one APPR. These counts describe the supplied filings only and are not measures of total company portfolio, sales or safety performance. No recall records appear in the supplied sample. [1][2][3]
The record identifies Saluda Medical Pty, Ltd. as the applicant on each filing. No parent company, brand owner or commercial partner is verified in these sources, and the relationship between the Australian applicant entity and the U.S. contact address in the clinical manual is not established by the filings. Details such as ownership, website, customer base, certification status and commercial availability remain unknown from the public information. [3][9]
